Overview
This is a table of pharmaceuticals and medical procedures for the treatment of Myasthenia Gravis, including trade names, nonproprietary (generic) names, and manufacturers1.
Table
| Nonproprietary (Generic) Name or Procedure | Trade Name | Company |
|---|---|---|
| Caffeine | ||
| Deltasone | Prednisone | |
| IVIG | ||
| RNA CAR T-cell (rCAR-T) therapy | Descartes-08 | Cartesian Therapeutics |
| Thymectomy | ||
| azathioprine | Azasan | Bausch Health |
| batoclimab | IMVT-1401 | Immunovant |
| cemdisiran | Alnylam Pharmaceuticals | |
| eculizumab | Soliris | Alexion |
| efgartigimod | Vyvgart | argenx |
| efgartigimod alfa-fcab | Vyvgart Hytrulo | argenx |
| gefurulimab | ALXN1720 | Alexion |
| inebilizumab | Uplizna | Horizon |
| mycophenolate | CellCept | Genentech |
| mycophenolic acid | Myfortic | Novartis |
| nipocalimab | JNJ-80202135 | Janssen |
| pozelimab | Veopoz | Regeneron |
| pyridostigmine | Mestinon | Bausch Health |
| ravulizumab | Ultomiris | Alexion |
| rituximab | Rituxan | Genentech |
| rozanolixizumab | Rystiggo | UCB |
| tolebrutinib | Sanofi | |
| zilucoplan | Zilbrysq | UCB |